SCHEMBL4866252

SCHEMBL4866252

COc1ccc(CNc2nc(-c3ccc(Cl)cc3)nc3ccccc23)cc1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 4/20 0.78
POLB P06746 3/20 0.69
LMNA P02545 3/20 0.65
USP2 O75604 1/20 0.65
ALDH1A1 P00352 1/20 0.65
CYP1A2 P05177 1/20 0.65
CYP3A4 P08684 1/20 0.65
CYP2D6 P10635 1/20 0.65
CYP2C9 P11712 1/20 0.65
TSHR P16473 1/20 0.65
MAPK1 P28482 1/20 0.65
CYP2C19 P33261 1/20 0.65
HSD17B10 Q99714 1/20 0.65
CLK4 Q9HAZ1 1/20 0.65
ACP1 P24666 1/20 0.65
APP P05067 2/20 0.64
MEN1 O00255 4/20 0.63
KMT2A Q03164 4/20 0.63
GBA1 P04062 1/20 0.63
ATM Q13315 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12176338 1.00 PDE5A (0.78) PDE5APOLBLMNAUSP2ALDH1A1
SCHEMBL12176090 0.94 LMNA (0.72) PDE5APOLBLMNAUSP2ALDH1A1
SCHEMBL12176088 0.92 LMNA (0.76) PDE5APOLBLMNAUSP2ALDH1A1
SCHEMBL2580707 0.90 MEN1 (0.77) PDE5APOLBLMNAUSP2ALDH1A1
SCHEMBL27899407 0.90 LMNA (0.67) PDE5APOLBLMNAUSP2ALDH1A1
SCHEMBL27899415 0.89 MAPK1 (0.63) PDE5APOLBLMNAUSP2ALDH1A1
SCHEMBL4863831 0.88 CYP1A2 (0.74) PDE5ALMNAUSP2ALDH1A1CYP1A2
SCHEMBL2591972 0.88 PDE5A (1.00) PDE5APOLBLMNAUSP2ALDH1A1
SCHEMBL2583256 0.88 PDE5A (0.90) PDE5APOLBLMNAUSP2ALDH1A1
SCHEMBL12176337 0.86 PDE5A (0.85) PDE5APOLBLMNAMAPK1APP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080207614-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2008-08-28 US claimed
JP-2008526734-A 2008-07-24 JP claimed
EP-1844023-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2007-10-17 EP claimed
WO-2006071095-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2006-07-06 WO claimed
US-20080207614-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2008-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207614-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY GPR119, GCKR, GLP1R PDE5A 204/4885POLB 4499/4885LMNA 3549/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.